MAC of Sevoflurane in end stage kidney disease
Phase 1
- Conditions
- Renal transplantation is the curative treatment in patients with endstage kidney disease. These patients have altered intraoperativeanesthetic requirements compared with patients with maintained renalfunction. Sevoflurane is used for anesthesia in patients with end stagekidney disease. However, it is unknown if whether Sevoflurane has thesame potency as in patients with maintained renal function. Theminimum alveolar concentration is a measure of the potency of volatileanesthetics.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Registration Number
- EUCTR2015-003141-25-AT
- Lead Sponsor
- Medical University Vienna, Department of Anesthesia, Intensive Care Medicine and Pain Management
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Age 30-65
Study group
End stage kidney disease (GFR < 30ml/min/1.72m2)
Renal transplantation
Control group
Skin incision on the abdomen of around 10cm
Maintained kidney function (GFR > 60ml/min/1.72m2)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 48
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Age < 30, > 65 years old
History of malignant Hypothermia
Hypokalemia > 5,5mmol/l
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method